<DOC>
	<DOCNO>NCT00839111</DOCNO>
	<brief_summary>The purpose study evaluate Progression-Free Survival ( PFS ) time Sorafenib combination FOLFIRI regimen use second front treatment patient advance CRC failure oxaliplatin treatment .</brief_summary>
	<brief_title>Sorafenib FOLFIRI Regimen 2nd Colorectal Cancer ( CRC ) After Failure Oxaliplatin Treatment</brief_title>
	<detailed_description>This phase Ⅱ open label , non randomize study , sorafenib use combination irinotecan , leucovorin fluorouracil patient advance colorectal cancer failure oxaliplatin treatment.The aim study determine Progression-Free Survival ( PFS ) Sorafenib use combination FOLFIRI regimen second front treatment patient advance CRC failure oxaliplatin treatment , define time treatment disease progression death due cause . The secondary endpoint disease control rate , define complete response , partial response , stable disease.Response rate , overall survival , safety also evaluate .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Provision write informed consent 2 . Histological cytological confirm adenocarcinoma colon rectum 3 . Age 18 75 year . 4 . Patient metastatic disease fail least 2 cycle oxaliplatinbased systemic chemotherapy , exclude adjuvant chemotherapy . Disease progression proven radiological evidence . A duration 28 day oxaliplatin therapy also require . 5 . ECOG Performance Status 0 or1 6 . Life expectancy least 12 week 7 . The required evidence measurable lesion least 10 mm long diameter spiral compute tomography scan 20 mm conventional technique ( RECIST criterion ) 8 . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 Platelet count 100,000/μl Total bilirubin &lt; 1.5 time upper limit normal ALT AST &lt; 2.5 x ULN ( &lt; 5 x ULN patient liver involvement cancer ) ALP &lt; 4 x ULN PTINR/PTT &lt; 1.5 x upper limit normal Serum creatinine &lt; 1.5 x ULN 1 . Patients unable swallow oral medication 2 . History cardiac disease : congestive heart failure &gt; NYHA class 2 active CAD ( MI 6 mo prior study entry allow ) cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension 3 . History HIV infection chronic hepatitis B C ( high copy number HBV ) . 4 . Active clinically serious infection ( &gt; grade 2 NCICTC version 3.0 ) 5 . Symptomatic metastatic brain meningeal tumor ( unless patient &gt; 6 month definitive therapy , negative imaging study within 4 week study entry clinically stable respect tumor time study entry ) 6 . Patients seizure disorder require medication ( steroids antiepileptic ) 7 . History organ allograft , The organ allograft may allow protocol specific . 8 . Patients undergoing renal dialysis 9 . Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma within 5 year . 10 . Patients evidence history bleed diathesis.Significant haemorrhage ( &gt; 30 ml/bleeding episode previous 3 month ) , haemoptysis ( &gt; 5 ml fresh blood previous 4 week ) thrombotic event ( include transient ischaemic attack ) previous 12 month . 11. chronic inflammatory bowel disease ; ileus ; genetic fructose intolerance 12 . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result . 13 . Any condition unstable could jeopardize safety patient compliance study 14 . Pregnant breastfeeding patient . Women childbearing potential must negative pregnancy test perform within 7 day start treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial ( men least 3 month last administration study medication ) . 15 . Prior exposure study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>Progression free survival</keyword>
	<keyword>Toxicity</keyword>
	<keyword>Response rate</keyword>
	<keyword>overall survival</keyword>
</DOC>